J&J To Power Ahead With 10 Launches In Four Years
Set To Outpace Sector Again
Executive Summary
Johnson & Johnson has achieved exceptional growth in recent years, and a raft of new products is set to sustain it further.
You may also be interested in...
Deal Watch: Genentech Gets Access To X-Chem’s DNA-Encoded Library Technology
Genentech will use the X-Chem platform to obtain leads against multiple oncology targets. Lilly partners with Merus on CD3-targeting T-cell therapy candidates.
Deal Watch: Merck's Busy Stretch Includes Collaborations With Dewpoint, Zymeworks
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.
J&J’s Gorsky Hails Strong Performance By Immunology Therapies Tremfya, Stelara
A strong fourth quarter and full-year 2019 performance by J&J was driven by significant sales growth for Tremfya and Stelara. CFO Wolk said a $4bn opioids settlement remains on track.